Innovative immunotherapies in Oncology
Developing first-in-class biologics designed to overcome previously unaddressed immune evasion mechanisms.
Novel approaches for immune-mediated diseases
Advancing novel drugs that target key pathological pathways in a differentiated approach to restore immune homeostasis
Pipeline
Biond’s pipeline includes three clinical-stage oncology programs, alongside a portfolio of discovery and preclinical programs in immune-mediated diseases.
Our oncology pipeline features first-in-class Phase 2 and Phase 1 programs targeting key pathological pathways:
In parallel, our immune-mediated disease pipeline includes novel programs in discovery and preclinical stages, focused on innovative approaches to modulate the immune system.
Products
BND-22
BND-22, is a Phase 2 anti-ILT2 blocking antibody, with efficacy in solid tumors particularly in CRC and cholangiocarcinoma patients with both anti-PD-1 agents and cetuximab, including in patients who had relapsed on cetuximab and presented with liver metastases, with an ongoing Phase 2 study at MD Anderson in CRC, cholangiocarcinoma, and ovarian cancer.
BND-67
BND-67 is a first-in-class antibody-based therapy for preventing pathological CD28 shedding in cancer patients. BND-67’s unique mechanism enhances effector T-cell activity while selectively inhibiting regulatory T-cells, offering a differentiated and highly targeted approach to drive potent anti-tumor immunity.
BND-35
BND-35, is an innovative antibody targeting the Ig-like transcript 3 (ILT3) receptor, in development for the treatment of solid tumors known to have a suppressive tumor microenvironment (TME). BND-35 was shown to be safe with no dose limiting toxicities as monotherapy in the dose escalation trial.
News
SAR881 ESMO Oral Presentation
Final results of a Phase 1 clinical study evaluating SAR444881, a first-in-class antibody targeting the immune checkpoint protein ILT2, for patients with advanced solid tumors.
11th Annual Oncology Innovation Forum
Biond Biologics was pleased to participate in the 11th Annual Oncology Innovation Forum, where our CEO and Co-Founder, Dr. Tehila Ben Moshe, presented BND-67, our first-in-class immuno-oncology program targeting CD28 shedding.
SAR881 ESMO Oral Presentation
Final results of a Phase 1 clinical study evaluating SAR444881, a first-in-class antibody targeting the immune checkpoint protein ILT2, for patients with advanced solid tumors.
All rights reserved Biond Biologics © 2026